Drug intelligence / Profile preview

Baqi Lingmao formula

Development stage: Unknown
Lead developer: Shanghai University of Traditional Chinese Medicine
Administration: Oral

Overview

Baqi Lingmao formula is a Traditional Chinese Medicine (TCM) herbal formulation developed by Shuguang Hospital, affiliated with the Shanghai University of Traditional Chinese Medicine. It is primarily investigated for its therapeutic potential in treating primary liver cancer (hepatocellular carcinoma), chronic hepatitis B, and HBV-related liver cirrhosis. The formula is often used as an adjuvant therapy alongside Western medications such as sorafenib or entecavir to improve clinical outcomes, reduce disease progression, and manage symptoms. Its pharmacological profile is characterized by anti-fibrotic and anti-tumor properties typical of complex herbal mixtures used in hepatology.

Other names: Baqi Lingmao recipeBaqi Lingmao decoctionLingmao GranulesLingmao Keli八七灵猫方

Beyond the preview

Go deeper on Baqi Lingmao formula.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Baqi Lingmao formula.

Explore the full profile